Showing results (131-140 of 170) with videos related to
Sort By:
Pageof 17
Clinical Medicine (London, England)|April 1, 2015
Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathwaysPetros Perros, Colin M Dayan, A Jane Dickinson, et al.Brain Communications|June 6, 2022
Coupling cognitive and brainstem dysfunction in multiple sclerosis-related chronic neuropathic limb painPeter Foley, Yazhuo Kong, Ramune Dirvanskiene, et al.Survey of Ophthalmology|February 19, 2022
Dupilumab-associated ocular manifestations: A review of clinical presentations and managementDuoduo Wu, Benjamin S Daniel, Andre J X Lai, et al.JAAD International|August 19, 2021
A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)Clare L Rogers, Matthew Gibson, Johannes S Kern, et al.The Australasian Journal of Dermatology|August 3, 2019
Atopic dermatitis in adults: An Australian management consensusSaxon Smith, Christopher Baker, Kurt Gebauer, et al.The British Journal of Dermatology|March 29, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trialBrett King, Benjamin Ehst, Peter Foley, et al.Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.Pageof 17